Inovio Pharmaceuticals, Inc. (INO)

NCM – Real vaqt narxi. Valyuta: USD

0.77

+0.00 (0.55%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

0.81

+0.04 (4.91%)

Bozordan keyin: Aug 12, 2026, 6:03 PM EDT

12.08.2026

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term investments anticipated to fund operations into late first quarter 2027, through a potential launch of INO-3107, if approved PLYMOUTH MEETING, Pa., Aug. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments.

05.08.2026

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

04.08.2026

INOVIO to Report Second Quarter Financial Results on August 12, 2026

PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its second quarter 2026 financial results will be released after the market close on August 12th, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

12.08.2026

Inovio Pharmaceuticals, Inc. (INO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Bet on 5 Top-Ranked Stocks With Rising P/E

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Videolar

No Data

Press-relizlar

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Bet on 5 Top-Ranked Stocks With Rising P/E

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Videolar

No Data

Press-relizlar

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Search stocks

Inovio Pharmaceuticals, Inc. (INO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Bet on 5 Top-Ranked Stocks With Rising P/E

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Videolar

No Data

Press-relizlar

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Bet on 5 Top-Ranked Stocks With Rising P/E

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Videolar

No Data

Press-relizlar

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights